Journal article 3 views
Alzheimer's diagnosis beyond cerebrospinal fluid: Probe-Free Detection of Tau Proteins using MXene based redox systems and molecularly imprinted polymers
Ajith Mohan Arjun 
,
Sudhaunsh Deshpande,
Tom Dunlop ,
Beth Norman,
Daniela Oliviera,
Georgeta Vulpe,
Felismina Moreira,
Sanjiv Sharma
,
Sudhaunsh Deshpande,
Tom Dunlop ,
Beth Norman,
Daniela Oliviera,
Georgeta Vulpe,
Felismina Moreira,
Sanjiv Sharma
Biosensors and Bioelectronics:X
Swansea University Authors:
Tom Dunlop , Georgeta Vulpe, Sanjiv Sharma
Abstract
Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI M...
| Published in: | Biosensors and Bioelectronics:X |
|---|---|
| Published: |
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa66925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI MIP) for the sensitive detection of Tau-441 in interstitial fluid (ISF) and plasma. The VxPDA/PANI MIP sensor demonstrates a broad detection range of 5 fg/mL to 5 ng/mL (122 aM/L to 122 pM/L) in ISF without the use of redox mediators, with a lower limit of detection (LOD) of 2.3 fg/mL (60 aM/L). Furthermore, a handheld device utilizing this technology successfully detects Tau-441 in artificial serum with high sensitivity (5 fg/mL to 150 fg/mL (122 aM/L to 366 aM/L)) and specificity within a clinically relevant range. The rapid detection time (~32 minutes) and low cost (~£20/device) of this sensor highlight its potential for minimally invasive, early AD diagnosis in clinical settings. This advancement aims to facilitate a transition away from invasive cerebrospinal fluid (CSF)-based diagnostic techniques for AD. |
|---|---|
| College: |
Faculty of Science and Engineering |
| Funders: |
The authors thank the MRC-AMED UK-Japan project (Multi-analyte prognostic and diagnostic screening in blood and skin for Alzheimer's disease, MR/X02153X/1) for their support. We also thank AIM providing SEM, EDS, and XPS facilities. AIM is funded in part by the EPSRC (EP/M028267/1), the European Regional Development Fund through the Welsh Government (80708) and the Welsh Government's Ser Cymru Program. |